Company profile
Corcept Therapeutics Incorporated
Pipeline10 assets
- Relacorilantglucocorticoid receptor / selective cortisol modulator / EndocrinologyHypercortisolism (GRACE)Phase IIIFiledHypercortisolism associated with adrenal adenoma or hyperplasia (GRADIENT)Phase IIIFiledLong-term safety extensionPhase IIFiled
- KorlymKorlym / glucocorticoid receptor / cortisol modulator / EndocrinologyPrevalence and treatment of hypercortisolism in difficult-to-control type 2 diabetes (CATALYST)Phase IV
- LifyorliLifyorli / glucocorticoid receptor / selective cortisol modulator / OncologyPlatinum-resistant ovarian cancer (ROSELLA)Phase IIIApproved
- Relacorilant + Nab-paclitaxel + Bevacizumabglucocorticoid receptor / selective cortisol modulator combination / OncologyPlatinum-resistant ovarian cancer (BELLA Arm A)Phase IIPlatinum-sensitive ovarian cancer (BELLA Arm B)Phase III
- Relacorilant + Nab-paclitaxelglucocorticoid receptor / selective cortisol modulator combination / OncologyEndometrial cancer (BELLA Arm C)Phase IICervical cancer (STELLA)Phase II
- Relacorilant + Nab-paclitaxel + Gemcitabineglucocorticoid receptor / selective cortisol modulator combination / OncologyPancreatic cancer (TRIDENT)Phase II
- Nenocorilant + Nivolumabglucocorticoid receptor / selective cortisol modulator combination / OncologySolid tumors (SYNERGY)Phase II
- Relacorilant + Enzalutamideglucocorticoid receptor / selective cortisol modulator combination / OncologyProstate cancerPhase II
- Dazucorilantglucocorticoid receptor / selective cortisol modulator / NeurologyALS (DAZALS)Phase II
- Miricorilantglucocorticoid receptor / selective cortisol modulator / MetabolismMASH (MONARCH)Phase II
Latest news0 items
All newsNo recent headlines yet.
New company coverage will appear here as soon as it is picked up.